The NF1 gene, a putative tumor suppressor gene, contains a GAP related domain (GRD) which accelerates hydrolysis of ras-bound GTP to GDP, thereby converting the ras oncogene from its active to inactive form. Two forms of the NF1 GRD transcript (Type I and Type II) are dierentially expressed in neuroectodermal tumor tissue relative to dierentiated neural cells, and in gastric cancer cell lines relative to normal stomach mucosa. We measured relative expression of NF1 Type II and Type I isoforms in cultured normal and malignant human ovarian surface epithelial cells(HOSE) and in invasive and borderline ovarian tumor tissue. We demonstrated an 11-fold increase in Type II: Type I ratio in 7 HOSE cultures relative to eight ovarian cancer cell lines. Our ®ndings indicate a signi®cant decrease in Type II isoform expression and increase in Type I expression in ovarian cancer cells and tumor tissue relative to HOSE cells. We also demonstrate an increase in Type II: Type I ratio, and a decrease in cell proliferation rate in three ovarian cancer cell lines on treatment with retinoic acid. We propose that dierential expression of the NF1 Type I and Type II isoforms is related to cellular dierentiation in ovarian epithelial cancer and strategies based on alteration in NF1 isoform expression may have therapeutic potential in ovarian malignancies.
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Keywords: ovary; cancer; NF1; retinoic acid Ovarian cancer is the ®fth most common cancer and the fourth leading cause of cancer death among women in the United States. It is the leading cause of death by gynecologic malignancy. While much of our understanding of the genetic basis of ovarian cancer remains speculative, evidence indicates that development of ovarian tumors requires a series of genetic changes involving dominant oncogenes, mismatch repair genes, and a large number of tumor suppressor genes (Cliby et al., 1993; Tangir et al., 1996; Phillips et al., 1996; Lu et al., 1997; Sato et al., 1991; Wertheim et al., 1994 Wertheim et al., , 1996 Rodabaugh et al., 1995; Mazars et al., 1991) .
The neuro®bromatosis type 1 (NF1) gene derives its name from an autosomal dominantly inherited disorder aecting approximately one in 3500 individuals. The disorder is characterized by tumors of the peripheral nervous system and developmental abnormalities including multiple tumors of various origins which aect several organ systems (Riccardi, 1981) . The NF1 gene, ®rst mapped in 1987 (Barker et al., 1987; Goldgar et al., 1987; Seizinger et al., 1987) , is a 300 ± 350 kilobase gene encoding at least 2818 amino acides which maps to chromosome 17q (Marchuk et al., 1991) . NF1 is commonly accepted as one of several known tumor suppressor genes (Skuse and Ludlow, 1995) . Its mRNA and 250 ± 327 kDa protein product are widely expressed in many tissues (Wallace et al., 1990) .
Evidence supports the role of the NF1 gene as a tumor suppressor gene which aects the regulation of ras. The NF1 gene contains a region, the NF1 GAP related domain (GRD), which is similar in function and sequence to catalytic domains of the mammalian GTPase activating protein (GAP) (Xu et al., 1990) and to yeast IRA proteins (Tanaka et al., 1990) , both of which mediate the hydrolysis of ras-bound GTP which is an active form of ras to an inactive GDP-bound form (McCormick et al., 1988; Vogel et al., 1988) . Schwannoma cell lines expressing low levels of NF1 protein product contain abnormally high levels of active GTP-bound ras. Introduction into schwannoma cell lines of cDNA encoding the GAP induced morphological reversion of the cells and decreased the proportion of GTP-bound ras (DeClue et al., 1992) . It has been proposed that the NF1 GRD product suppresses malignant tumor growth by interacting with ras proteins and accelerating ras GTPase activity (DeClue et al., 1992; Martin et al., 1990) .
The NF1 GRD has been found to contain a 63 bp insertion (exon 23a) which is dierentially expressed in neuroectodermal tumors and in gastric cancer cells. The NF1 isoform containing exon 23a (Type II) is predominantly expressed in adult brain tissue and in neural cells. An alternatively spliced form of NF1 in which exon 23a is deleted (Type I) is predominantly expressed in undierentiated neuroectodermal tumors and in fetal brain tissue. Studies suggest that a relationship exists between relative expression of the Type II and Type I transcripts and cell dierentiation. Induction of neural cell dierentiation by retinoic acid has been shown to cause a shift in expression from the Type I to the Type II isoform (Nishi et al., 1991) . Increased expression of the Type I isoform has been demonstrated in gastric cancer cell lines relative to normal stomach mucosa, which predominantly ex-presses the Type II isoform (Uchida et al., 1992) . Data also suggest that dierential expression of the Type I and Type II transcripts is related to ras activity. Coinfection of ®broblasts with NF1 Type I protein and H-ras inhibited the ability of ras to induce reporter gene expression (Al-Alawi et al., 1993) . Both the NF1 Type I and Type II proteins have been shown to increase conversion of GTP-bound ras to its GDPbound form (Anderson et al., 1993) . The 21 amino acid insert contained in the Type II isoform has been shown to alter the structure of the NF1 GRD signi®cantly, potentially altering its catalytic activity (Nishi et al., 1991) . Diering speci®c activities among three GTPase activating proteins including the NF1 Type I protein product has been demonstrated. The NF1 Type I protein exhibits a 30-fold lower speci®c activity for ras inactivation than Type I GAP, another GTPase which aects ras activity. It has been proposed that dierential expression of the NF1 GRD transcripts modulates ras activity by their diering catalytic activities.
High frequency of LOH has been observed at the NF1 locus as well as decreased expression of the NF1 gene in ovarian epithelial tumor tissue and cancer cell lines (Iyengar et al., 1996) . To elucidate further a possible role of the NF1 gene in sporadic epithelial ovarian cancer, we describe in this study the relative expression of dierent types of NF1 isoforms in cultured normal and malignant human ovarian surface epithelial cells and in invasive and borderline ovarian tumor tissues. Normal HOSE cells are derived from the germinal epithelium of the ovary and are believed to be the normal counterparts for the epithelial ovarian carcinoma cells (Auersperg et al., 1998) . All seven of the normal HOSE cultures studied predominantly expressed the Type II NF1 mRNA isoform. The average ratio of Type II : Type I of all HOSE cultures was 5.6 ( Figure 1 ). Five of eight ovarian cancer cell lines studied (OVCA432, OVCA3, OVCA433, CAOV3, OVCA420) showed predominant expression of the Type I isoform with an average ratio of Type II : Type I of 0.5. One of the cell lines, OVCA429, showed approximately equal expression of the two isoforms with a ratio of 1.0. Two cancer cell lines (SKOV3 and DOV13) exhibited patterns of expression similar to normal HOSE cultures with Type II :Type I ratios of 4.5 and 7.5 respectively (Figure 1 ).
Of 11 serous adenocarcinoma tissues studied, eight predominantly expressed the Type I isoform with an average ratio of Type II : Type I of 0.8; two expressed both forms equally and one predominantly expressed the Type II isoform with a ratio of 1.2. All ®ve borderline ovarian tumor samples studied predominantly expressed the Type I isoform with an average ratio of Type II : Type I of 0.7 (Figure 2 ). One benign ovarian cyst (case 359) predominantly expressed the Type II isoform with a Type II : I ratio of 9.5. The dierence in average Type II : Type I ratio between borderline tumor and serous adenocarcinoma was not statistically signi®cant.
The dierence between the average ratio of Type II : Type I in tumor tissue and HOSE cultures is statistically signi®cant (P510 78 ). The dierence between the average ratio of Type II : Type I in ovarian cancer cell lines and HOSE is signi®cant (P50.01). Two cancer cell lines (SKOV3-13 and DOV13) exhibit patterns of expression consistent with normal surface epithelium. There is no signi®cant dierence between the Type II : I ratio of tumor tissues and ovarian cancer cell lines. Absolute expression of the Type II isoform by HOSE cultures was on average 2.5-fold greater than Type II expression by ovarian cancer cell lines. Absolute expression of the Type I isoform by ovarian cancer cell lines was on average 3.0-fold greater than that of HOSE cultures. The dierence in the absolute expression of the Type II isoform between normal HOSE cultures and cancer cell lines was statistically signi®cant (P50.001). The dierence between absolute expression of the Type I isoform was not statistically Figure 1 Semi-quantitative RT ± PCR analysis on six normal HOSE cell cultures (HOSE1, 10, 13, 15, 16 and 17) , one immortalized HOSE cell line (HOSE6E6E7) and seven ovarian carcinoma cell lines using primer pairs speci®c to the NF1 GRD and b-actin. HOSE cell cultures and immortalized HOSE cell line were established by previously described methods (Tsao et al., 1995) . The ovarian carcinoma cell lines used for this study include DOV13, OVCA433, OVCA432, OVCA429, OVCA420 and DOV13. Total RNAs were ®rst isolated from cells as described (Iyengar et al., 1996) . cDNA was synthesized by reverse transcription of 1 mg of total cellular RNA, 50 units of Moloney murine leukemia virus reverse transcriptase, 2.5 mM Random hexamers, 16PCR Buer (50 mM KCl, 10 mM Tris-HCl, pH 8.3), 5 mM MgCl 2 , 1 mM each dNTP, 20 units RNAsin. The 20 ml reaction mixtures were incubated at room temperature for 10 min at 428C for 30 min heated to 998C for 10 min and chilled on ice. PCR was then performed using primers spanning exon 23a, NF1G.C and NF1G.D as described previously (Uchida et al., 1992) . PCR products were loaded onto a 5% non-denaturing polyacrylamide gel. The electrophoresis gel was run at a constant 120 V, dried and exposed to X-ray ®lm. Expression of the Type II and Type I isoforms and of b-actin was quantitated by densitometer (BIO RAD Model GS-700 Imaging Densitometer and Molecular Analyst Software, Bio-Rad Laboratories, Hercules, CA, USA). Absolute expression of both isoforms was quantitated by measuring maximum optical density of each band. Relative expression of the two isoforms was calculated as the ratio of the Type II: Type I isoform for cancer cell lines and normal HOSE cultures. b-actin expression was measured. Statistical signi®cance of dierences in expression between groups of samples was determined using a two-tailed Student's t-test. Arrowhead indicates the PCR product generated from the NF1 Type II isoform (A) Densitometry results for each sample are summarized in (B) signi®cant; however if CAOV 3 and SKOV 3 are excluded the dierence was signi®cant (P50.03). Similar patterns were also observed in both borderline and invasive ovarian tumor tissues using the normal HOSE primary culture as a control. These results suggest that expression of the Type II isoform is signi®cantly decreased and Type I isoform is increased in ovarian cancer cells and tumor tissues.
Several studies have linked dierential expression of NF1-GRD Type I and Type II transcripts to degree of cellular dierentiation. Schwann cells stimulated by high doses of forskolin or 8-bromo-cAMP which induce a dierentiated phenotype have been shown to express predominantly the Type II NF1 isoform as well as increased levels of the NF1 protein product relative to untreated cells. Untreated cells, in contrast, predominantly express the Type I NF1 isoform . The dierential expression of NF1 type I and II isoforms has also been associated with dierentiation of neuroectodermal tumors and development of brain tumors. Adult brain tissue has been shown to express predominantly the Type II isoform, while fetal brain tissue expresses predominantly the Type I transcript. (Nishi et al., 1991) . Increased expression of the Type I transcript has been demonstrated in gastric cancer cell lines relative to normal stomach mucosa and in undierentiated hepatoblastoma cell lines relative to normal liver cell culture and an undierentiated hepatoblastoma cell line (Uchida et al., 1992) . Mutant NF1 GRD's have been shown to induce morphological reversion of a ras transformed mammalian cell line (Nakafuku et al., 1993) . Our results are consistent with these studies and suggest that the malignant transformation of more dierentiated normal HOSE cells to ovarian carcinoma cells may correlate with a change in Type II : Type I ratio.
Observation of a consistent pattern of dierential expression of the Type II and Type I isoforms of the NF1 GRD in neuroectodermal tumors, gastric cancer, and now ovarian cancer cell lines relative to dierentiated cells of each respective tissue suggests that a correlation exists between alternative splicing at the NF1 GRD and tumorigenesis. It is important to elucidate the mechanisms that lead to down-regulation of the Type II NF1 in these tumors. Furthermore, the dierent catalytic activities associated with NF1 Type II and Type I transcripts along with the ability of the NF1 GRD proteins to negatively regulate ras activity raise interesting questions about the role which the dierential expression of the NF1 GRD Type I and Type II proteins may play in the development of a number of malignant phenotypes.
Of six cell lines treated with retinoic acid, three (OVCA420, OVCA429 and OVCA432) demonstrated a decrease in the Type II : Type I ratio on treatment for 6 days at both 2 mM and 20 mM concentrations. The ratio doubled from 0.5 in untreated OVCA420 cells to 1.2 after 6 days of treatment (Figure 3) . The magnitude of the shift was identical at both dosages. The shift in OVCA429 appeared to be dose dependent, with the Type II : I ratio increasing from 0.9 to 1.0 after 4 days and to 1.1 after 6 days of treatment at 2 mm retinoic acid. At 20 mm, the ratio increased to 1.1 after 4 days and to 1.2 after 6 days of treatment. OVCA432 exhibited a ®vefold increase in Type II : Type I ratio (0.4 to 2.2) on RA treatment. SKOV3-13, CAOV3 and HOSE1-15 did not exhibit altered NF1 isoform expression on RA treatment (data not shown). The type II : Type I ratio of untreated cells remained constant at 2 and 6 days for all cell lines.
Cell proliferation (MTT) assay was performed to evaluate the eect of retinoic acid on the growth of both malignant and immortalized ovarian epithelial cell lines. Four ovarian carcinoma cell lines OVCA420, OVCA429, OVCA432, and CAOV3 showed significantly reduced growth rates after retinoic acid treatment at 2 mM (Figure 4) . The growth rate was further reduced when these cells were treated at 20 mM (data not shown). Among these lines, the growth inhibition in OVCA429 appeared to be dose dependent, with the growth rate decreased approximately by 20% after 6 days of treatment at 2 mM retinoic acid and by 60% at 20 mM. The immortalized HOSE cell line (HOSE1-15) and one cancer cell line (SKOV3-13) showed no signi®cant reduction in growth rate even after 12 days of retinoic treatment at both 2 and 20 mM concentrations.
The increase in Type II : Type I ratio and decreased in growth rates observed in OVCA420, OVCA429 and OVCA432 suggests that there may be a relationship between NF-1 isoform expression and cell growth rate. Retinoic acid has been shown to inhibit cell growth Figure 2 Semi-quantitative RT ± PCR analysis on one normal HOSE cell cultures (HOSE10), 11 invasive ovarian carcinomas (case 316, 319, 341, 345, 349, 351, 357, 393, 402, 419 and 425) , ®ve serous borderline ovarian tumors (case 333, 405, 466, 469 and 481) , and one benign ovarian tumor (case 359) using primer pairs speci®c to the NF1-GRD and b-actin. Surgical specimens of human ovarian tumor tissue were obtained under a protocol approved by the Human Subjects Committee of the Brigham and Women's Hospital. All histopathologic diagnoses were con®rmed by a gynecologic pathologist. Invasive carcinomas were graded, and all tumors were surgically staged according to the International Federation of Gynecology and Obstetrics (FIGO) criteria (International Federation of Gynecology and Obstetrics, 1987) . Arrowhead indicates the PCR product generated from the NF1 Type II isoform (A). Densitometry results for each sample are summarized in (B) and to induce dierentiation in a number of cell types including neuroblastoma, prostatic adenocarcinoma, breast cancer, ovarian adenocarcinoma and salivary gland adenocarcinoma (Sidell and Koeer, 1988; Jing et al., 1977; Langdon et al., 1988; Reese et al., 1983; Azuma et al., 1988) and it has been shown to increase the Type II/Type I ratio in undierentiated neuroectodermal cells (neuroblastoma) but not on well differentiated astrocytoma (Nishi et al., 1991) . One hypothesis based on these ®ndings and supported by the results of our study is that the relative expression of the NF1 Type I and Type II isoforms aects cell growth and dierentiation in certain cancer cell lines. This regulation may occur by the diering catalytic activities of the various isoforms which, due to alternative splicing of the GAP related domain, dier in their abilities to regulate ras activity.
Three ovarian cancer cell lines (CAOV3, SKOV3-13 and OVCA433) did not show an isoform shift on treatment with retinoic acid. SKOV3, which exhibits a Type II : Type I ratio consistent with normal HOSE cultures yet possesses growth characteristics of a cancer cell line, may develop by carcinogenesis pathways which are independent of NF1 expression. As ovarian carcinogenesis involves many dierent mutational events, it is plausible and expected to observe variations in pathways among dierent cell lines. In the case of OVCA433 which predominantly expresses the Type I isoform characteristic of the majority of cancer cell lines studied, the absence of growth inhibition and isoform shift in response to retinoic acid treatment may be due to decreased sensitivity to retinoic acid. A previous study of the OVCA433 cancer cell line has also demonstrated absence of cytostasis on treatment with retinoic acid (Brooks et al., 1991) . The mechanism by which cell lines are rendered insensitive Figure 3 RT ± PCR analysis on ovarian carcinoma cell lines (OVCA420, 429 and 432) which have been treated with all tans retinoic acid (2 mM and 20 mM) for 2 days and 6 days using primer pair speci®c to the NF1-GRD. Retinoic acid stock solution of 250 mM in ethanol (Sigma Chemical Co., St Louis, MO, USA) was diluted in culture medium to 2 mM and 20 mM concentrations. Ethanol concentration in medium did not exceed 0.03 mM. Cells were cultured in 75 m 2¯a sks (12¯asks each cell line) or 96-well plates. On reaching 60% con¯uency, cells were treated with retinoic acid at 0 mM, 2 mM concentrations and harvested after 2 and 6 days of treatment for RNA extraction. The medium was changed every third day. Arrows indicate the PCR products generated from the NF1 Type II isoform (A). The ratio of Type II to Type I isoform for each cell line is indicated in (B) Figure 4 Histogram showing the growth rates of one immortalized HOSE cell line (HOSE6E6E7) and six ovarian carcinoma cell lines which have been treated with 2 mM all trans retinoic acid for 6, 9 and 12 days. Cells were seeded at a concentration of 2610 3 cells/well in 100 ml culture medium into 96-well plates. Five replicates for each cell line were used. Retinoic acid was ®rst dissolved in ethanol and added to the culture medium at concentrations of 2 mM and 20 mM. Equal volume of ethanol was also added to each cell line as control. Culture medium was changed every three days and the cells were harvested on day 6, 9, and 12 for the MTT cell proliferation assay (Boehringer Mannheim, Indianapolis, IN, USA). Brie¯y, 10 ml of MTT labeling solution was added to each well and incubated at 378C for 4 h. Subsequently, 100 ml solubilization solution was added and the microtiter plate was incubated at 378C overnight. The absorbance of the formagen product was then measured at wavelength 550 nm to retinoic acid is not clearly understood. While in human ovarian adenocarcinoma cell lines, the relationship between nuclear retinoic acid receptor expression and response to retinoic acid is unclear (Caliaro et al., 1994; Harant et al., 1993) . Recent study of cytoplasmic retinoic acid binding protein expression in 11 breast cancer cell lines suggests that sensitivity to treatment with retinoic acid is related to the cell's ability to constitutively express high levels of a speci®c type of cytoplasmic retinoic acid receptor on RA induction (Jing et al., 1997) . It is plausible that OVCA433 does not undergo an isoform shift on treatment with retinoic acid due to relative insensitivity conferred by alteration in retinoic acid receptor expression. In the case of CAOV3, which did not undergo an isoform shift, but which demonstrated decreased proliferation on retinoic acid treatment, one explanation is that some event occurs in the carcinogenesis of this line which uncouples the regulation of growth in this cell line by retinoic acid from NF1 isoform expression. Clearly the NF1 GRD mediated pathway which we are proposing is not identical across all cell lines, but appears to play a role in at least three lines studied. Further studies should include transfection of Type II into ovarian cancer cell lines, and conversely of Type I into HOSE cells with observation for dierentiation and transformation respectively along with measurement of ras activity.
In conclusion, our results indicate that a shift from the predominant expression of Type II towards expression of the Type I isoform of NF1 may be related to the development of both invasive and borderline epithelial ovarian tumors, and that in certain cell lines RA may induce cancer cells to shift expression from the Type I towards the Type II isoform. This isoform shift is accompanied by a decrease in cell proliferation rate. Our ®ndings support the evidence that the alternatively spliced NF1 Type I and Type II isoforms have dierent regulatory properties which aect cell dierentiation and tumorigenesis. Strategies based on alteration in NF1 isoform expression may have therapeutic potential in ovarian malignancies.
